US Patent

US9169307 — Potent compstatin analogs

Method of Use · Assigned to University of Pennsylvania Penn · Expires 2027-11-18 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses compounds that bind to the C3 protein and inhibit complement activation, displaying improved activity compared to existing compounds.

USPTO Abstract

Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3541`	—
`U-4244`	—

Patent Metadata

Patent number: US9169307
Jurisdiction: US
Classification: Method of Use
Expires: 2027-11-18
Drug substance claim: Yes
Drug product claim: No
Assignee: University of Pennsylvania Penn
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.